JP2007190369A - 改善された薬剤放出特性を備えた薬剤溶出物品 - Google Patents
改善された薬剤放出特性を備えた薬剤溶出物品 Download PDFInfo
- Publication number
- JP2007190369A JP2007190369A JP2006337295A JP2006337295A JP2007190369A JP 2007190369 A JP2007190369 A JP 2007190369A JP 2006337295 A JP2006337295 A JP 2006337295A JP 2006337295 A JP2006337295 A JP 2006337295A JP 2007190369 A JP2007190369 A JP 2007190369A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- eluting article
- pharmacologically active
- polymer
- active compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 183
- 229940079593 drug Drugs 0.000 title claims abstract description 170
- 150000001875 compounds Chemical class 0.000 claims abstract description 163
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 131
- 239000000758 substrate Substances 0.000 claims abstract description 15
- 229920000642 polymer Polymers 0.000 claims description 245
- 238000006731 degradation reaction Methods 0.000 claims description 33
- 230000015556 catabolic process Effects 0.000 claims description 32
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 20
- 229960002930 sirolimus Drugs 0.000 claims description 20
- -1 poly (alkyl methacrylate Chemical compound 0.000 claims description 18
- 229920001577 copolymer Polymers 0.000 claims description 16
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 14
- 229920000954 Polyglycolide Polymers 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000004633 polyglycolic acid Substances 0.000 claims description 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 13
- 208000037803 restenosis Diseases 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 9
- 230000002965 anti-thrombogenic effect Effects 0.000 claims description 8
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 8
- 229920002732 Polyanhydride Polymers 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 229920002477 rna polymer Polymers 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 102000008946 Fibrinogen Human genes 0.000 claims description 5
- 108010049003 Fibrinogen Proteins 0.000 claims description 5
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 5
- 229920001710 Polyorthoester Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229940123237 Taxane Drugs 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 229940012952 fibrinogen Drugs 0.000 claims description 5
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 5
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 5
- 239000002745 poly(ortho ester) Substances 0.000 claims description 5
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical group C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 5
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 5
- 229950009819 zotarolimus Drugs 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229940116355 PI3 kinase inhibitor Drugs 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 230000003872 anastomosis Effects 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 4
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 3
- 229960005330 pimecrolimus Drugs 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 150000002605 large molecules Chemical class 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 abstract description 13
- 239000013047 polymeric layer Substances 0.000 abstract 5
- 239000010410 layer Substances 0.000 description 194
- 239000000463 material Substances 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 14
- 229920002988 biodegradable polymer Polymers 0.000 description 12
- 239000004621 biodegradable polymer Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229920001600 hydrophobic polymer Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- JZAFRYPNQHUUMQ-UHFFFAOYSA-N Viridiol Natural products OC1C(OC)C(O)C2(C)C3=CC=C4C(=O)CCC4=C3C(=O)C3=C2C1=CO3 JZAFRYPNQHUUMQ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001849 poly(hydroxybutyrate-co-valerate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000306 polymethylpentene Polymers 0.000 description 2
- 239000011116 polymethylpentene Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 2
- JZAFRYPNQHUUMQ-KNTRFNDTSA-N viridiol Chemical compound C1([C@@]2([C@H]([C@@H](OC)[C@H]3O)O)C)=CC=C4C(=O)CCC4=C1C(=O)C1=C2C3=CO1 JZAFRYPNQHUUMQ-KNTRFNDTSA-N 0.000 description 2
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 0 C*C(C[C@@](C)C([C@@]([C@@](C(I=N)=C[C@@](C)C(C[C@@]([C@](*)C[C@](C)(CC[C@]1O)CC1OC)OC([C@](CCCC1)N1C(C1O)O)=O)=O)O)OC)=O)C=CC=CC=C(*)[C@@](*)C[C@](CC[C@]2*)O[C@@]12O Chemical compound C*C(C[C@@](C)C([C@@]([C@@](C(I=N)=C[C@@](C)C(C[C@@]([C@](*)C[C@](C)(CC[C@]1O)CC1OC)OC([C@](CCCC1)N1C(C1O)O)=O)=O)O)OC)=O)C=CC=CC=C(*)[C@@](*)C[C@](CC[C@]2*)O[C@@]12O 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- GRXCKJZIMLJEIW-UHFFFAOYSA-N OC(C(=O)O)CCC.C(CCCC)(=O)O Chemical compound OC(C(=O)O)CCC.C(CCCC)(=O)O GRXCKJZIMLJEIW-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000710 anti-hyperplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- RTACIUYXLGWTAE-UHFFFAOYSA-N buta-1,3-diene;2-methylbuta-1,3-diene;styrene Chemical compound C=CC=C.CC(=C)C=C.C=CC1=CC=CC=C1 RTACIUYXLGWTAE-UHFFFAOYSA-N 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229920005680 ethylene-methyl methacrylate copolymer Polymers 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
- A61L2300/61—Coatings having two or more layers containing two or more active agents in different layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/300,821 US10029034B2 (en) | 2005-12-15 | 2005-12-15 | Drug-eluting articles with improved drug release profiles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007190369A true JP2007190369A (ja) | 2007-08-02 |
| JP2007190369A5 JP2007190369A5 (https=) | 2009-03-26 |
Family
ID=37964483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006337295A Pending JP2007190369A (ja) | 2005-12-15 | 2006-12-14 | 改善された薬剤放出特性を備えた薬剤溶出物品 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10029034B2 (https=) |
| EP (1) | EP1808167B1 (https=) |
| JP (1) | JP2007190369A (https=) |
| CA (1) | CA2571302C (https=) |
| ES (1) | ES2686778T3 (https=) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540921A (ja) * | 2006-06-22 | 2009-11-26 | ボストン サイエンティフィック リミテッド | 医療機器の為の放出制御薬物コーティング |
| JP2010155041A (ja) * | 2008-12-29 | 2010-07-15 | Korea Inst Of Science & Technology | ナノ構造パターンを有する薬物放出用ステントの製造方法及びこれにより製造した薬物放出用ステント |
| JP2010264253A (ja) * | 2007-09-04 | 2010-11-25 | Japan Stent Technology Co Ltd | 薬剤徐放性ステント |
| JP2011502009A (ja) * | 2007-10-31 | 2011-01-20 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 低速溶解ポリマーを有する埋込型デバイス |
| JP2011512957A (ja) * | 2008-02-29 | 2011-04-28 | スミス アンド ネフュー インコーポレーテッド | 生物医学的応用のための勾配コーティング |
| JP2011520557A (ja) * | 2008-05-21 | 2011-07-21 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 非晶質下塗り層及び半結晶性貯蔵層を含むコーティング |
| JP2012016593A (ja) * | 2010-07-08 | 2012-01-26 | Tyco Healthcare Group Lp | 自己解離可能な医療デバイス |
| JP2012517319A (ja) * | 2009-02-11 | 2012-08-02 | ナンヤン テクノロジカル ユニヴァーシティ | 多層外科的プロテーゼ |
| JP2012529922A (ja) * | 2009-06-15 | 2012-11-29 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | ポリ（エチレングリコール）及びポリ（ラクチド−グリコリド）のブロックコポリマーを含む埋込型医療機器及びそのためのコーティング物 |
| JP2012236787A (ja) * | 2011-05-11 | 2012-12-06 | Fujifilm Corp | 複合フィルム |
| JP2012254296A (ja) * | 2011-06-07 | 2012-12-27 | Taewoong Medical Co Ltd | 薬物放出ステントコーティング剤の製造方法及びこれによって製造された薬物放出ステントコーティング剤 |
| JP2013523258A (ja) * | 2010-03-31 | 2013-06-17 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 埋込み型デバイス用の吸収性コーティング |
| US8591571B2 (en) | 2009-03-02 | 2013-11-26 | Japan Stent Technology Co., Ltd. | Drug-eluting stent |
| US8697110B2 (en) | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
| US8697113B2 (en) | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
| US9090745B2 (en) | 2007-06-29 | 2015-07-28 | Abbott Cardiovascular Systems Inc. | Biodegradable triblock copolymers for implantable devices |
| US10258777B2 (en) | 2016-02-18 | 2019-04-16 | Terumo Kabushiki Kaisha | Drug treatment method and delivery device |
| WO2019103098A1 (ja) * | 2017-11-22 | 2019-05-31 | テルモ株式会社 | 薬剤付与器具および薬剤層の形成方法 |
| KR102290367B1 (ko) * | 2020-08-28 | 2021-08-19 | (주)솔시온바이오메디칼 | 기공 내에 생리활성화 물질을 함유한 기공성 다층의 관형 구조체 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036984A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
| US8263102B2 (en) | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| US7671095B2 (en) | 2006-05-31 | 2010-03-02 | The Trustees Of The Boston University | Films and particles |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| WO2008057328A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| US20080255658A1 (en) * | 2007-04-12 | 2008-10-16 | Medtronic Vascular, Inc. | Degradation Associated Drug Delivery for Drug Eluting Stent and Medical Device Coatings |
| US8057876B2 (en) * | 2008-02-25 | 2011-11-15 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with layers having different degradation rates |
| US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
| US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
| WO2009140131A2 (en) * | 2008-05-13 | 2009-11-19 | The Trustees Of Boston University | Compliant composites for application of drug-eluting coatings to tissue surfaces |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| WO2012091680A1 (en) * | 2010-12-30 | 2012-07-05 | Nanyang Technological University | A device for controlled release of a bioactive agent |
| US9867880B2 (en) * | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| EP2994174A1 (en) | 2013-05-06 | 2016-03-16 | Abbott Cardiovascular Systems Inc. | A hollow stent filled with a therapeutic agent formulation |
| CN107427668B (zh) * | 2015-01-22 | 2021-09-03 | 因特尔赛克特耳鼻喉公司 | 药物涂覆的气囊 |
| BR112017026746B1 (pt) | 2015-06-18 | 2023-11-28 | Acuitybio Corporation | Composições de liberação de fármacos implantáveis e uso de uma mistura compreendendo copolímero de plga, peg 8000 e paclitaxel |
| CN111542364B (zh) * | 2017-12-27 | 2022-07-15 | 株式会社钟化 | 导管及其制造方法 |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| KR102402859B1 (ko) * | 2020-06-17 | 2022-05-30 | 한국과학기술연구원 | 3차원으로 연결된 유연한 나노 구조 필름을 포함하는 약물 방출용 스텐트의 제조 방법 및 이에 의해 제조된 약물 방출용 스텐트 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824048A (en) * | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
| JP2003533493A (ja) * | 2000-05-12 | 2003-11-11 | コーディス・コーポレイション | 再狭窄の予防に有効な薬剤の組み合わせ |
| WO2004012676A2 (en) * | 2002-08-02 | 2004-02-12 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| WO2005004945A2 (en) * | 2003-06-25 | 2005-01-20 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of a drug eluting implantable medical device |
| JP2005270658A (ja) * | 2004-03-22 | 2005-10-06 | Cordis Corp | 脈管の傷害後の再狭窄を防ぐためのラパマイシンとの組み合わせにおけるパンゼム（登録商標）の局所的脈管配給 |
| JP2005305154A (ja) * | 2004-04-15 | 2005-11-04 | Cordis Corp | 脆弱性プラークの治療のためのラパマイシンおよび１７ベータ−エストラジオールの組み合わせ物の局所的投与 |
| WO2005115493A2 (en) * | 2004-05-27 | 2005-12-08 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
| US20060122264A1 (en) * | 2003-06-09 | 2006-06-08 | Yasumi Uchida, Etal | Stem cell invasion inhibitor |
| WO2006116989A2 (de) * | 2005-05-05 | 2006-11-09 | Hemoteq Ag | Vollflächige beschichtung von gefässstützen |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2133815A1 (en) * | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
| AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| US5747060A (en) * | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
| SE0000363A0 (sv) * | 2000-02-04 | 2001-08-05 | Zoucas Kirurgkonsult Ab | Belagd medicinsk anordning |
| AU9486901A (en) * | 2000-09-29 | 2002-04-08 | Cordis Corp | Coated medical devices |
| US20020113183A1 (en) * | 2001-01-12 | 2002-08-22 | Magla Products, L.L.C. | Merchandise display system |
| JP4062622B2 (ja) * | 2001-06-08 | 2008-03-19 | ネイチャーワークス・エル・エル・シー | 単環式エステル及びカーボネートの共重合体並びにその製造方法 |
| US6927898B2 (en) * | 2001-08-15 | 2005-08-09 | Photon-X, Llc | Ultra-wide bandwidth optical amplifier |
| US7056338B2 (en) | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
| US20050163821A1 (en) * | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
| EP1539270A1 (en) | 2002-09-18 | 2005-06-15 | Medtronic Vascular, Inc. | Controllable drug releasing gradient coatings for medical devices |
| US20050070989A1 (en) * | 2002-11-13 | 2005-03-31 | Whye-Kei Lye | Medical devices having porous layers and methods for making the same |
| WO2004110315A1 (en) * | 2003-06-16 | 2004-12-23 | Nanyang Technological University | Polymeric stent and method of manufacture |
| EP1638624B1 (en) | 2003-06-19 | 2013-10-30 | Vascular Therapies, LLC | Vascular closure device |
| US20060275341A1 (en) * | 2005-06-02 | 2006-12-07 | Miv Therapeutics Inc. | Thin foam coating comprising discrete, closed-cell capsules |
-
2005
- 2005-12-15 US US11/300,821 patent/US10029034B2/en active Active
-
2006
- 2006-12-12 EP EP06256316.8A patent/EP1808167B1/en not_active Not-in-force
- 2006-12-12 ES ES06256316.8T patent/ES2686778T3/es active Active
- 2006-12-14 JP JP2006337295A patent/JP2007190369A/ja active Pending
- 2006-12-14 CA CA2571302A patent/CA2571302C/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824048A (en) * | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
| JP2003533493A (ja) * | 2000-05-12 | 2003-11-11 | コーディス・コーポレイション | 再狭窄の予防に有効な薬剤の組み合わせ |
| WO2004012676A2 (en) * | 2002-08-02 | 2004-02-12 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| US20060122264A1 (en) * | 2003-06-09 | 2006-06-08 | Yasumi Uchida, Etal | Stem cell invasion inhibitor |
| WO2005004945A2 (en) * | 2003-06-25 | 2005-01-20 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of a drug eluting implantable medical device |
| JP2005270658A (ja) * | 2004-03-22 | 2005-10-06 | Cordis Corp | 脈管の傷害後の再狭窄を防ぐためのラパマイシンとの組み合わせにおけるパンゼム（登録商標）の局所的脈管配給 |
| JP2005305154A (ja) * | 2004-04-15 | 2005-11-04 | Cordis Corp | 脆弱性プラークの治療のためのラパマイシンおよび１７ベータ−エストラジオールの組み合わせ物の局所的投与 |
| WO2005115493A2 (en) * | 2004-05-27 | 2005-12-08 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
| WO2006116989A2 (de) * | 2005-05-05 | 2006-11-09 | Hemoteq Ag | Vollflächige beschichtung von gefässstützen |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013024959; Ｊ Ｂｉｏｍｅｄ Ｍａｔｅｒ Ｒｅｓ Ｐｔ Ａ．， Ｖｏｌ．７１Ａ Ｎｏ．４ Ｐａｇｅ．６２５-６３４ （２００４） * |
Cited By (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540921A (ja) * | 2006-06-22 | 2009-11-26 | ボストン サイエンティフィック リミテッド | 医療機器の為の放出制御薬物コーティング |
| US9468707B2 (en) | 2007-06-29 | 2016-10-18 | Abbott Cardiovascular Systems Inc. | Biodegradable triblock copolymers for implantable devices |
| US9090745B2 (en) | 2007-06-29 | 2015-07-28 | Abbott Cardiovascular Systems Inc. | Biodegradable triblock copolymers for implantable devices |
| US8641756B2 (en) | 2007-09-04 | 2014-02-04 | Japan Stent Technology Co., Ltd. | Sustained drug-releasing stent |
| JP2013126558A (ja) * | 2007-09-04 | 2013-06-27 | Japan Stent Technology Co Ltd | 薬剤徐放性ステント |
| JP2010264253A (ja) * | 2007-09-04 | 2010-11-25 | Japan Stent Technology Co Ltd | 薬剤徐放性ステント |
| JP5368991B2 (ja) * | 2007-09-04 | 2013-12-18 | 株式会社日本ステントテクノロジー | 薬剤徐放性ステント |
| JP2013126557A (ja) * | 2007-09-04 | 2013-06-27 | Japan Stent Technology Co Ltd | 薬剤徐放性ステント |
| US9040111B2 (en) | 2007-09-04 | 2015-05-26 | Japan Stent Technology Co., Ltd. | Method of making a stent |
| US8968392B2 (en) | 2007-09-04 | 2015-03-03 | Japan Stent Technology Co., Ltd. | Method of inhibiting vascular intimal hyperplasia using stent |
| JP2011502009A (ja) * | 2007-10-31 | 2011-01-20 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 低速溶解ポリマーを有する埋込型デバイス |
| US8889170B2 (en) | 2007-10-31 | 2014-11-18 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating with a triblock copolymer |
| US9345668B2 (en) | 2007-10-31 | 2016-05-24 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
| US9629944B2 (en) | 2007-10-31 | 2017-04-25 | Abbott Cardiovascular Systems Inc. | Implantable device with a triblock polymer coating |
| JP2017060889A (ja) * | 2008-02-29 | 2017-03-30 | スミス アンド ネフュー インコーポレイテッド | 生物医学的応用のための勾配コーティング |
| JP2015057126A (ja) * | 2008-02-29 | 2015-03-26 | スミス アンド ネフュー インコーポレーテッド | 生物医学的応用のための勾配コーティング |
| JP2011512957A (ja) * | 2008-02-29 | 2011-04-28 | スミス アンド ネフュー インコーポレーテッド | 生物医学的応用のための勾配コーティング |
| US9011965B2 (en) | 2008-02-29 | 2015-04-21 | Smith & Nephew, Inc. | Gradient coating for biomedical applications |
| US8697113B2 (en) | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
| JP2011520557A (ja) * | 2008-05-21 | 2011-07-21 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 非晶質下塗り層及び半結晶性貯蔵層を含むコーティング |
| US9592323B2 (en) | 2008-05-21 | 2017-03-14 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
| JP2014221398A (ja) * | 2008-05-21 | 2014-11-27 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 非晶質下塗り層及び半結晶性貯蔵層を含むコーティング |
| US8661630B2 (en) | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
| JP2010155041A (ja) * | 2008-12-29 | 2010-07-15 | Korea Inst Of Science & Technology | ナノ構造パターンを有する薬物放出用ステントの製造方法及びこれにより製造した薬物放出用ステント |
| JP2012517319A (ja) * | 2009-02-11 | 2012-08-02 | ナンヤン テクノロジカル ユニヴァーシティ | 多層外科的プロテーゼ |
| JP2015147098A (ja) * | 2009-02-11 | 2015-08-20 | ナンヤン テクノロジカル ユニヴァーシティＮａｎｙａｎｇ Ｔｅｃｈｎｏｌｏｇｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ | 多層外科的プロテーゼ |
| US9486302B2 (en) | 2009-02-11 | 2016-11-08 | Nanyang Technological University | Multi-layered surgical prosthesis |
| US8591571B2 (en) | 2009-03-02 | 2013-11-26 | Japan Stent Technology Co., Ltd. | Drug-eluting stent |
| US8697110B2 (en) | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
| JP2012529922A (ja) * | 2009-06-15 | 2012-11-29 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | ポリ（エチレングリコール）及びポリ（ラクチド−グリコリド）のブロックコポリマーを含む埋込型医療機器及びそのためのコーティング物 |
| JP2016193203A (ja) * | 2010-03-31 | 2016-11-17 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 埋込み型デバイス用の吸収性コーティング |
| US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
| JP2013523258A (ja) * | 2010-03-31 | 2013-06-17 | アボット カーディオヴァスキュラー システムズ インコーポレイテッド | 埋込み型デバイス用の吸収性コーティング |
| JP2012016593A (ja) * | 2010-07-08 | 2012-01-26 | Tyco Healthcare Group Lp | 自己解離可能な医療デバイス |
| JP2012236787A (ja) * | 2011-05-11 | 2012-12-06 | Fujifilm Corp | 複合フィルム |
| JP2012254296A (ja) * | 2011-06-07 | 2012-12-27 | Taewoong Medical Co Ltd | 薬物放出ステントコーティング剤の製造方法及びこれによって製造された薬物放出ステントコーティング剤 |
| US10258777B2 (en) | 2016-02-18 | 2019-04-16 | Terumo Kabushiki Kaisha | Drug treatment method and delivery device |
| WO2019103098A1 (ja) * | 2017-11-22 | 2019-05-31 | テルモ株式会社 | 薬剤付与器具および薬剤層の形成方法 |
| JPWO2019103098A1 (ja) * | 2017-11-22 | 2020-11-19 | テルモ株式会社 | 薬剤付与器具および薬剤層の形成方法 |
| JP7198218B2 (ja) | 2017-11-22 | 2022-12-28 | テルモ株式会社 | 薬剤付与器具および薬剤層の形成方法 |
| KR102290367B1 (ko) * | 2020-08-28 | 2021-08-19 | (주)솔시온바이오메디칼 | 기공 내에 생리활성화 물질을 함유한 기공성 다층의 관형 구조체 |
| WO2022045642A1 (ko) * | 2020-08-28 | 2022-03-03 | (주)솔시온바이오메디칼 | 기공 내에 생리활성화 물질을 함유한 기공성 다층의 관형 구조체 |
| JP2023536107A (ja) * | 2020-08-28 | 2023-08-23 | メディンテル コー リミティッド | 気孔内に生理活性物質を含有する気孔性多層管状構造体 |
| JP7496494B2 (ja) | 2020-08-28 | 2024-06-07 | メディンテル コー リミティッド | ポア内に生理活性物質を含有する多層管状構造体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1808167B1 (en) | 2018-07-04 |
| ES2686778T3 (es) | 2018-10-19 |
| US20070141112A1 (en) | 2007-06-21 |
| CA2571302C (en) | 2014-11-18 |
| EP1808167A1 (en) | 2007-07-18 |
| US10029034B2 (en) | 2018-07-24 |
| CA2571302A1 (en) | 2007-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007190369A (ja) | 改善された薬剤放出特性を備えた薬剤溶出物品 | |
| EP2291431B1 (en) | Bio-degradable block co-polymers for controlled release | |
| EP1549276B1 (en) | Drug eluting coatings for medical implants | |
| US6918929B2 (en) | Drug-polymer coated stent with pegylated styrenic block copolymers | |
| US20060198868A1 (en) | Biodegradable coating compositions comprising blends | |
| US20060147491A1 (en) | Biodegradable coating compositions including multiple layers | |
| EP2442841B1 (en) | Implantable medical devices and coatings therefor comprising block copolymers of poly (ethylene glycol) and a poly (lactide-glycolide) | |
| US8518097B2 (en) | Plasticized stent coatings | |
| AU2004308654B2 (en) | Pharmaceutical Compositions | |
| JP2007190369A5 (https=) | ||
| US20100119578A1 (en) | Extracellular matrix modulating coatings for medical devices | |
| US20070128289A1 (en) | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases | |
| WO2007121065A2 (en) | Durable biocompatible controlled drug release polymeric coatings for medical devices | |
| US7264822B2 (en) | Conjugated drug-polymer coated stent | |
| HK1221918A1 (en) | Mtor inhibitor eluting medical device | |
| HK1221918B (en) | Mtor inhibitor eluting medical device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071130 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120928 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130828 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130926 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151126 |